Vancouver, British Columbia, and Sacramento, California--(Newsfile Corp. - October 23, 2025) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic", or the "Company"), a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of breast cancers, announces the release of a new video interview with the Company's CEO in partnership with Departures Capital.
The interview delves into the Company's story and near-term execution plan around its flagship device, IzoView, a dedicated breast CT platform. In the discussion, CEO Bob Thast shares the founding vision and leadership context, then unpacks IzoView's features while explaining the science, patient implications, and how it differentiates in the breast-imaging market. He outlines planned use of proceeds over the next 12-18 months, including three devices and capital for a forthcoming U.S. FDA clinical study, one partner device in the U.K. while initiating CE-mark activities, and two additional devices for markets that accept the CE-mark-focused on building data to accelerate regulatory pathways and time-to-market. Thast also discusses Izotropic's exclusive CADx patent for breast CT, and future recurring revenues beyond device sales, while candidly addressing key regulatory, clinical, and market risks into 2026 and mitigation strategies. Watch the full interview here to learn more: https://www.youtube.com/watch?v=LFeUW7J2jYU.
About Izotropic:
More information about Izotropic Corporation can be found on its corporate website at izocorp.com, its educational website at breastct.com, and by reviewing its profile on SEDAR+ at sedarplus.ca.
Forward-Looking Statements:
This document may contain statements that are "Forward-Looking Statements," which are based upon the current estimates, assumptions, projections, and expectations of the Company's management, business, and its knowledge of the relevant market and economic environment in which it operates. The Company has tried, where possible, to identify such information and statements by using words such as "anticipate," "believe," "envision," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," "contemplate" and other similar expressions and derivations thereof in connection with any discussion of future events, trends or prospects or future operating or financial performance, although not all forward-looking statements contain these identifying words.
These statements are not guarantees of performance and involve risks, including those related to capital requirements and uncertainties that are difficult to control or predict, and as such, they may cause future results of the Company's activity to differ significantly from the content and implications of such statements. Forward-Looking Statements are pertinent only as of the date on which they are made, and the Company undertakes no obligation to update or revise any Forward-Looking Statements to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law. Neither the Company nor its shareholders, officers, and consultants shall be liable for any action and the results of any action taken by any person based on the information contained herein, including, without limitation, the purchase or sale of Company securities. Nothing in this document should be deemed to be medical or other advice of any kind. All images are for illustrative purposes only. IzoView has not yet been approved or cleared for sale.
Contacts:
Robert Thast, Interim Chief Executive Officer
Telephone: 1-604-220-5031 or 1-833-IZOCORP ext. 1
Email: bthast@izocorp.com
James Gagnon, International Communications
Telephone: 1-604-780-7576 or 1-833-IZOCORP ext. 2
Email: jgagnon@izocorp.com
General and Corporate Inquiries
Telephone: 1-604-825-4778 or 1-833-IZOCORP ext. 3
Email: info@izocorp.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/271531
The interview delves into the Company's story and near-term execution plan around its flagship device, IzoView, a dedicated breast CT platform. In the discussion, CEO Bob Thast shares the founding vision and leadership context, then unpacks IzoView's features while explaining the science, patient implications, and how it differentiates in the breast-imaging market. He outlines planned use of proceeds over the next 12-18 months, including three devices and capital for a forthcoming U.S. FDA clinical study, one partner device in the U.K. while initiating CE-mark activities, and two additional devices for markets that accept the CE-mark-focused on building data to accelerate regulatory pathways and time-to-market. Thast also discusses Izotropic's exclusive CADx patent for breast CT, and future recurring revenues beyond device sales, while candidly addressing key regulatory, clinical, and market risks into 2026 and mitigation strategies. Watch the full interview here to learn more: https://www.youtube.com/watch?v=LFeUW7J2jYU.
About Izotropic:
More information about Izotropic Corporation can be found on its corporate website at izocorp.com, its educational website at breastct.com, and by reviewing its profile on SEDAR+ at sedarplus.ca.
Forward-Looking Statements:
This document may contain statements that are "Forward-Looking Statements," which are based upon the current estimates, assumptions, projections, and expectations of the Company's management, business, and its knowledge of the relevant market and economic environment in which it operates. The Company has tried, where possible, to identify such information and statements by using words such as "anticipate," "believe," "envision," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," "contemplate" and other similar expressions and derivations thereof in connection with any discussion of future events, trends or prospects or future operating or financial performance, although not all forward-looking statements contain these identifying words.
These statements are not guarantees of performance and involve risks, including those related to capital requirements and uncertainties that are difficult to control or predict, and as such, they may cause future results of the Company's activity to differ significantly from the content and implications of such statements. Forward-Looking Statements are pertinent only as of the date on which they are made, and the Company undertakes no obligation to update or revise any Forward-Looking Statements to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law. Neither the Company nor its shareholders, officers, and consultants shall be liable for any action and the results of any action taken by any person based on the information contained herein, including, without limitation, the purchase or sale of Company securities. Nothing in this document should be deemed to be medical or other advice of any kind. All images are for illustrative purposes only. IzoView has not yet been approved or cleared for sale.
Contacts:
Robert Thast, Interim Chief Executive Officer
Telephone: 1-604-220-5031 or 1-833-IZOCORP ext. 1
Email: bthast@izocorp.com
James Gagnon, International Communications
Telephone: 1-604-780-7576 or 1-833-IZOCORP ext. 2
Email: jgagnon@izocorp.com
General and Corporate Inquiries
Telephone: 1-604-825-4778 or 1-833-IZOCORP ext. 3
Email: info@izocorp.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/271531
